"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
(strontium-89 chloride) Injection
Metastron (strontium-89) is a sterile, non-pyrogenic, aqueus solution of St rontium-89 Chloride for intravenous administration. The solution contains no preservative.
Each milliliter contains:
Strontium< Chloride 10.9 - 22.6 mg
Water for Injection q.s. to 1 mL
The radioactive concentration is 37 MBq/mL, 1 mCi/mL, and the specific activity is 2.96-6.17 MBq/mg, 80-167 μCi/mg at calibration. The pH of the solution is 4 - 7.5.
Strontium-89 decays by beta emission with a physical half-life of 50.5 days. The maximum beta energy is 1.463 MeV (100%). The maximum range of β- from Strontium-89 in tissue is approximately 8 mm.
Radioactive decay factors to be applied to the stated value for radioactive concentration at calibration, when calculating injection volumes at the time of administration, are given in Table 1.
Table 1: Decay of Strontium-89
|* Days before (-) or after (+) the calibration date stated on the vial.|
Last reviewed on RxList: 1/29/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Metastron Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.